Home Companies Catalysts Deep Dives
Galvokimig UCB9741 PHASE2
Drug Profile
ModalityMulti-specific antibody
RouteSC
Therapy AreaImmunology
Peak Sales Est$2000M
Formulations[]
Companies
UCB (ORIGINATOR)100%
Mechanism: IL-13/IL-17A/IL-17F inhibitor
Expert: Multi-specific antibody blocking IL-13, IL-17A and IL-17F
Everyday: Multi-specific antibody blocking IL-13, IL-17A and IL-17F
Targets: ["IL-17F","IL-13","IL-17A"]
Programs (1)
IndicationStageKey StudyRegional Status
Atopic dermatitisPHASE2Phase 2b[]
Upcoming Catalysts (1)
Galvokimig - Atopic Dermatitis - Ph2b - Start/Updates 2026
Data from Supabase · Updated 2026-03-24